Are Clinical Trials Becoming More Global?
The globalization of clinical trials is the subject of this analysis to find if there is an increase in non-traditional sites.
Industry observers and industry critics have, in recent years, pointed to the growing use of countries outside the traditional areas of North America and Europe as locations for the conduct of pharmaceutical industry sponsored clinical trials. To the critics in particular this globalization trend presents serious potential ethical and medical issues. Critics has asserted that patients involved in clinical trials conducted in these newer geographies may not be adequately informed. Nor may the site medical people be appropriately trained. Moreover, clinical trials may be conducted in countries which may never receive the study drug if and when it ever comes to the market in the larger markets of North America, Japan, and Europe. A prior question arises though. Are clinical trials actually becoming more global? Much of the confusion about the actual trend comes about because of inadequate data sources behind some of the claims, data sources such as the seriously limited Bioresearch Monitoring Information System (BMIS) 1572 database or ad hoc samples from published clinical trial studies. Fortunately the federally mandated database, ClinicalTrials.gov, presents a more comprehensive data source. Since 2008 site location has been a federally mandated field, with less than 3% missing data for a given site’s country location. In the 1990s there was a significant increase of phase 3 sites in Eastern Europe. The data demonstrate though that there has been virtually no change in phase 3 site location for studies begun and completed studies between 2008-2012. There is a lag in study dates because obviously only completed studies can be included in the analysis. As yet unpublished data through 2014 shows no change in the pattern since 2012.
Harold E. Glass, PhD, Dean's Professor, University of the Sciences in Philadelphia
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
